Recent development in pharmacogenomics: From candidate genes to genome-wide association studies

Expert Review of Molecular Diagnostics

Volumn 7, Issue 4, 2007, Pages 371-393

  Grant, Struan F A ^a   Hakonarson, Hakon ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Copy number variation; Genetics; Genome wide association; Pharmacogenomics; Single nucleotide polymorphism

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALICAFORSEN; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; DG 031; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOCORTICOID; HYDROCHLOROTHIAZIDE; INFLIXIMAB; INSULIN; INTERLEUKIN 12 ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METFORMIN; MLN 02; NATALIZUMAB; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; ROSIGLITAZONE; SALMETEROL; SIBUTRAMINE; SULFONYLUREA; TOLBUTAMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST;

ASTHMA; AUTISM; BREAST CANCER; CATARACT; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE PREDISPOSITION; DRUG FATALITY; DRUG RESPONSE; ENTERITIS; GENE INTERACTION; GENE MAPPING; GENE TECHNOLOGY; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GLAUCOMA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LUNG CANCER; MYELOID LEUKEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOPOROSIS; PHARMACOGENOMICS; PHENOTYPE; RETINA MACULA DEGENERATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; UNSPECIFIED SIDE EFFECT;

GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOMICS; GENOTYPE; HUMANS; PHARMACOGENETICS;

EID: 34447536645     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.4.371     Document Type: Review

References (15)

1. Cartwright CP. Pharmacogenetics: the Dx perspective. Expert Rev. Mol. Diagn. 1(4), 371-376 (2001).
2. Roses AD. Pharmacogenetics place in modern medical science and practice. Life Sci. 70(13), 1471-1480 (2002).
3. Roses AD. Pharmacogenetics and the practice of medicine. Nature 405(6788), 857-865 (2000).
4. Lin M, Aquilante C, Johnson JA, Wu R. Sequencing drug response with HapMap. Pharmacogenomics J. 5(3), 149-156 (2005).
5. Stoughton RB, Friend SH. How molecular profiling could revolutionize drug discovery. Nat. Rev. Drug Discov. 4(4), 345-350 (2005).
6. Phillips KA, Van Bebber SL. Measuring the value of pharmacogenomics. Nat. Rev. Drug Discov. 4(6), 500-509 (2005).
7. Wilkinson GR. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352(21), 2211-2221 (2005).
8. Voora D, Eby C, Linder MW et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb. Haemost. 93(4), 700-705 (2005).
9. Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther. 77(5), 341-352 (2005).
10. de Leon J, Susce MT, Pan RM et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry 66(1), 15-27 (2005).
11. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15), 1200-1205 (1998).
12. Dormann H, Neubert A, Criegee-Rieck M et al. Readmissions and adverse drug reactions in internal medicine: the economic impact. J. Int. Med. 255(6), 653-663 (2004).
13. Hakonarson H, Thorvaldsson S, Helgadottir A et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293(18), 2245-2256 (2005).
14. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br. Med. Bull. 56(4), 1054-1070 (2000).
15. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).